12/23
06:41 am
nnvc
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape [Yahoo! Finance]
Low
Report
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape [Yahoo! Finance]
12/23
06:30 am
nnvc
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
Low
Report
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
11/19
12:09 am
nnvc
NanoViricides, Inc. (NYSE: NNVC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
NanoViricides, Inc. (NYSE: NNVC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/15
06:50 am
nnvc
NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID [Yahoo! Finance]
Medium
Report
NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID [Yahoo! Finance]
11/15
06:30 am
nnvc
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
Medium
Report
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
11/8
11:07 pm
nnvc
NanoViricides, Inc. (NYSE: NNVC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
NanoViricides, Inc. (NYSE: NNVC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/4
12:00 am
nnvc
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
Medium
Report
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
10/25
11:05 pm
nnvc
NanoViricides, Inc. (NYSE: NNVC) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
NanoViricides, Inc. (NYSE: NNVC) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
10/22
06:30 am
nnvc
NanoViricides President Dr. Diwan to Present at the PODD Conference
Low
Report
NanoViricides President Dr. Diwan to Present at the PODD Conference
10/15
06:30 am
nnvc
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
Medium
Report
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
10/8
06:30 am
nnvc
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
Medium
Report
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
9/30
06:30 am
nnvc
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
High
Report
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID